Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).

A Phase I, Single Centre, Randomised, Interventional, Open-Label, Cross-Over Study to Evaluate the Pharmacokinetics (PK) and the Safety and Tolerability of a Total Daily Dose of 900mg of TETA 4HCL, Comparing a New Once Daily TETA 4HCL Formulation (300mg) (3x300mg Trientine Base Tablets, OD) With the Current Marketed Cuprior® Formulation (150mg) (3x150mg Trientine Base Tablets, BD) in Adult Healthy Male and Female Participants

A randomised, open-label study evaluating the pharmacokinetics, safety, and tolerability of a new once daily dose of 900mg of TETA 4HCL by comparing it against the current marketed Cuprior® formulation (450mg trientine base, twice daily) in healthy male and female participants.

Study Overview

• Status: Completed
• Conditions: Wilson's Disease
• Intervention / Treatment: Drug: 900mg TETA 4HCl Once Daily Formulation; Drug: 900mg TETA 4HCl Cuprior®

Detailed Description

This is a single centre, phase I, randomized, controlled trial with a crossover design to evaluate the pharmacokinetics (PK), safety, and tolerability of a new once daily TETA 4HCL formulation (300mg) (3x300mg trientine base tablets, OD) compared to the current marketed Cuprior® formulation (150mg) (3x150mg trientine base tablets, BD) in adult healthy male and female participants.

Participants: 26 healthy participants will be enrolled to ensure 24 participants complete the study, with a balanced gender split.

Treatment: Participants will be randomized to receive either the new or the current formulation of the drug, and then switch to the other formulation after a period of time (see study flow chart below).

To remain in line with current EU SmPC and US PIL, being:

• EU daily dose range of 450-975 mg of trientine base
• US daily dose range of 150-1500mg trientine base the following treatments will be administered according to the treatment allocation schedule below: A: 900mg TETA 4HCl once a day / new formulation = 3 tablets of 300mg trientine base as a single dose B: 900mg TETA 4HCl marketed Cuprior formulation = 6 tablets of 150mg trientine base in two equally divided doses

Patients will be randomised in a 1:1 ratio to either one of the following sequences:

Treatment Sequence Period 1 Period 2 Sequence 1 Treatment A Treatment B Sequence 2 Treatment B Treatment A

Assessments: Participants will be assessed for eligibility criteria and will be monitored closely throughout the study. Assessments will be performed during the study and at the end of the study follow-up visit.

Duration: The duration of the study will be up to approximately 7 weeks, from screening to follow-up:

• Screening will take place between days -28 and -2
• In-house period from D-1 to D3 with dosing on D1 of each treatment period
• Follow-up will take place on D7 of Treatment Period 2

At least 5 days and a maximum of 10 days between treatment period study drug administration

Objective: To evaluate the PK, safety, and tolerability of the new once daily TETA 4HCL formulation compared to the current marketed Cuprior® formulation.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SE1 1YR
    • Richmond Pharmacology Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age: 18 to 40 years
• Body weight: ≥ 50 kg
• BMI: 18.0 to 25.0 kg/m2
• Health: Generally healthy, with no clinically significant illnesses or surgeries in the past 12 weeks
• Willingness to comply with trial procedures and restrictions

Exclusion Criteria:

• Significant current or recurrent disease
• Acute significant disease or illness within 7 days before the start of the trial
• Clinically significant deviations in blood tests
• An estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2
• Positive test for alcohol, drugs of abuse, hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab)
• Pregnant or breastfeeding women
• History or regular use of tobacco or other nicotine-containing products within 6 months before the start of the trial
• Treatment with an investigational drug within 90 days or 5 half-lives (whichever is longer) or exposure to more than 3 investigational drugs within 12 months of first study drug administration
• Use of prescription medication (excluding female hormonal contraception or hormone replacement therapy)within 30 days or 5 half
• lives (whichever is longer) prior to first study drug administration, or use of over-the-counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations; Paracetamol use ≤2g per day is permitted) during the 14 days or 5 half-lives of the drug (whichever is longer) before first study drug administration
• History of sensitivity/allergy to the study medications or components thereof (mannitol, colloidal anhydrous silica, glycerol dibehenate or magnesium-stearate)
• Donation or loss of 450 mL or more of blood or plasma within 16 weeks prior to first trial medication administration or intention to donate blood in the 16 weeks after completing the trial
• An inability to follow a standardised diet and meal schedule or inability to fast, as required during the trial
• Participants deemed to have difficult veins for cannulation/blood draws

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Once Daily Dose Formulation (Treatment A); 1 x 900mg TETA 4HCl, new once daily formulation (3x300mg trientine base tablets as a single AM dose)	Drug: 900mg TETA 4HCl Once Daily Formulation; 3x300mg trientine base tablets as a single AM dose
Active Comparator: Cuprior® comparator (Treatment B); 2 x 450mg TETA 4HCl, Marketed Cuprior® formulation (6 x150mg trientine base tablets in two equally divided doses (450mg doses 8 hours apart)	Drug: 900mg TETA 4HCl Cuprior®; 6 x150mg trientine base tablets in two equally divided doses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma Concentrations (AUC) of TETA 4HCL Following Administration of Two TETA 4HCL Tablet Formulations.	PK parameters derived by non-compartmental methods including: AUC 24 and AUCinf. PK sampling was done pre-first dose and then post-first dose for Treatment A (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48. Post-first dose for Treatment B (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8 (before 2nd dose), 8.5, 9, 9.25, 9.5, 10, 11, 12, 13, 14, 16, 20, 24, 36, 48.	Up to 48 hours post first dose initiation.
Plasma Concentrations (AUC) of N1-acetyltriethylenetetramine (MAT) Following Administration of Two TETA 4HCL Tablet Formulations.	PK parameters derived by non-compartmental methods including: AUC 24 and AUCinf. PK sampling was done pre-first dose and then post-first dose for Treatment A (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48. Post-first dose for Treatment B (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8 (before 2nd dose), 8.5, 9, 9.25, 9.5, 10, 11, 12, 13, 14, 16, 20, 24, 36, 48.	Up to 48 hours post first dose initiation.
Plasma Concentrations (AUC) of N1, N10-diacetyltriethylenetetramine (DAT) Following Administration of Two TETA 4HCL Tablet Formulations.	PK parameters derived by non-compartmental methods including: AUC 24 and AUCinf. PK sampling was done pre-first dose and then post-first dose for Treatment A (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48. Post-first dose for Treatment B (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8 (before 2nd dose), 8.5, 9, 9.25, 9.5, 10, 11, 12, 13, 14, 16, 20, 24, 36, 48.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (AUC) of TETA in Plasma	PK parameters derived by non-compartmental methods including: AUCinf and AUC 24. PK sampling was done pre-first dose and then post-first dose for Treatment A (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48. Post-first dose for Treatment B (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8 (before 2nd dose), 8.5, 9, 9.25, 9.5, 10, 11, 12, 13, 14, 16, 20, 24, 36, 48.	Up to 48 hours post first dose initiation.
Plasma Concentrations (Cmax) of TETA 4HCL Following Administration of Two TETA 4HCL Tablet Formulations.	PK parameters derived by non-compartmental methods including: Cmax.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (Time) of TETA in Plasma	PK parameters derived by non-compartmental methods including: Thalf and Tmax.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (Concentration) of TETA in Plasma	PK parameters derived by non-compartmental methods including: Clast and Cmax.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (AUC) of MAT in Plasma	PK parameters derived by non-compartmental methods including: AUCinf and AUC 24. PK sampling was done pre-first dose and then post-first dose for Treatment A (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48. Post-first dose for Treatment B (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8 (before 2nd dose), 8.5, 9, 9.25, 9.5, 10, 11, 12, 13, 14, 16, 20, 24, 36, 48.	Up to 48 hours post first dose initiation
Plasma Concentrations (Cmax) of N1-acetyltriethylenetetramine (MAT) Following Administration of Two TETA 4HCL Tablet Formulations.	PK parameters derived by non-compartmental methods including: Cmax.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (Time) of MAT in Plasma	PK parameters derived by non-compartmental methods including: Thalf and Tmax..	Up to 48 hours post first dose initiation
Pharmacokinetic Parameters (Concentration) of MAT in Plasma	PK parameters derived by non-compartmental methods including: Clast and Cmax..	Up to 48 hours post first dose initiation
Pharmacokinetic Parameters (AUC) of DAT in Plasma	PK parameters derived by non-compartmental methods including: AUCinf and AUC 24. PK sampling was done pre-first dose and then post-first dose for Treatment A (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48. Post-first dose for Treatment B (hours): 0.5, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8 (before 2nd dose), 8.5, 9, 9.25, 9.5, 10, 11, 12, 13, 14, 16, 20, 24, 36, 48.	Up to 48 hours post first dose initiation.
Plasma Concentrations (Cmax) of N1, N10-diacetyltriethylenetetramine (DAT) Following Administration of Two TETA 4HCL Tablet Formulations.	PK parameters derived by non-compartmental methods including: Cmax.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (Time) of DAT in Plasma	PK parameters derived by non-compartmental methods including: Thalf and Tmax.	Up to 48 hours post first dose initiation.
Pharmacokinetic Parameters (Concentration) of DAT in Plasma	PK parameters derived by non-compartmental methods including: Clast and Cmax.	Up to 48 hours post first dose initiation.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To Compare the Safety and Tolerability of the Two TETA 4HCL Tablet Formulations.	The incidence, severity, and relationship of Treatment-Emergent Adverse Events (TEAEs).	Adverse events were collected from the patient signing the ICF until the end of study/follow-up (EOS/FU) visit. The Mean (Min, Max) number of days between signing ICF and the EOS/FU visit in the study was 20.2 (16, 25). All patients completed the study.

Collaborators and Investigators

• Sponsor: Orphalan
• Investigators: Principal Investigator: Thomas Ashdown, MBBCh Ssc, Richmond Pharmacology Limited

Study record dates

Study Major Dates

• Study Start (Actual): January 16, 2024
• Primary Completion (Actual): February 8, 2024
• Study Completion (Actual): February 16, 2024

Study Registration Dates

• First Submitted: November 2, 2023
• First Submitted That Met QC Criteria: November 7, 2023
• First Posted (Actual): November 13, 2023

Study Record Updates

• Last Update Posted (Estimated): August 15, 2025
• Last Update Submitted That Met QC Criteria: August 13, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Digestive System Diseases; Neurodegenerative Diseases; Liver Diseases; Movement Disorders; Heredodegenerative Disorders, Nervous System; Basal Ganglia Diseases; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Metal Metabolism, Inborn Errors; Hepatolenticular Degeneration; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Trientine
• Other Study ID Numbers: ORPH-131-012

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No